Neural Net Progression Model for NASH Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating Non-Alcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) are invasive, costly, and lack effective non-invasive predictive models, with existing treatments failing to address the underlying metabolic and inflammatory factors contributing to liver disease progression.
Innovation Solution
Development of a mathematical model and diagnostic system that uses biomarkers and a Neural Net Progression Model to predict liver biopsy results, incorporating interactions between metabolic syndrome factors and NASH to guide treatment decisions and monitor disease progression, alongside compositions that stimulate ileal brake hormones to manage insulin resistance and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If liver biopsy is used to diagnose and assess NASH progression, then measurement precision is improved, but ease of operation deteriorates due to invasiveness and complexity
Solution Approach 1:
The patent uses mathematical models and computational algorithms to create virtual copies of liver biopsy assessments. By analyzing serum biomarkers, imaging data, and clinical parameters through neural networks and regression models, the system reproduces the diagnostic information that would normally require invasive biopsy, thereby eliminating the need for surgical intervention while maintaining diagnostic accuracy.
2Measurement precision
If comprehensive biomarker analysis and mathematical modeling are implemented, then measurement precision is improved for predicting liver biopsy results, but device complexity increases
Solution Approach 1:
The patent develops a multi-functional diagnostic system where a single integrated platform performs multiple functions: analyzing serum biomarkers, processing imaging data, running mathematical models, and generating comprehensive risk assessments. The system uses universal algorithms that can evaluate various disease states (NAFLD, NASH, fibrosis, cirrhosis) and predict multiple outcomes (liver injury, cardiovascular events, mortality) through a unified analytical framework, reducing the need for separate specialized tools.
Solution Approach 2:
The patent introduces mathematical models and computational algorithms as intermediaries between raw clinical data and diagnostic conclusions. These intermediary systems process complex multi-parameter data (biomarkers, imaging, clinical history) through standardized algorithms, transforming disparate inputs into unified risk predictions. This intermediary layer simplifies the overall system by providing a structured processing framework that handles complexity internally while presenting simplified outputs to clinicians.
3Reliability
If existing treatments are used for NASH, then ease of operation is maintained, but reliability deteriorates because they fail to address underlying metabolic and inflammatory factors
Solution Approach 1:
The patent implements preliminary risk stratification and personalized treatment planning before initiating therapy. The mathematical models predict individual patient risk profiles for disease progression, cardiovascular events, and mortality, allowing clinicians to select and tailor treatments in advance based on predicted responses. This preliminary assessment ensures that treatments are chosen proactively to address specific patient needs rather than applying generic protocols, thereby improving reliability while managing complexity through advance planning.
Data Source
AI summary
The present invention is directed to a System characterization of NASH that combines Modeling and Biomarkers, enabling pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of Non Alcoholic Fatty Liver Disease (NAFLD) and Non Alcoholic Steatohepatitis (NASH). Said conditions are Liver related complications among the array of manifestations of metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, abdominal obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of NASH and NAFLD complications in patients with hepatitis viral infections, including Hepatitis B and Hepatitis C viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, metabolic syndrome complications including cardiovascular diseases, neurodegenerative diseases and premature ageing, among other disease states or conditions.